Jiangsu Hengrui Medicine Co., Ltd.
Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Hengrui was established in 1970 and listed in Shanghai Stock Exchange in 2000. The company ranks top 30 worldwide in pharmaceuticals industry by a market capitalization of over 30 billion USD, and is home to more than 21,000 employees worldwide. Hengrui not only stands out as a front-runner in cancer drugs, contrast agents, and surgical medicines, but is also a lead member of the National Anti-Tumor Medicine Technology Innovation Industry-Education-Research Alliance. Hengrui owns a National Targeted Drug Engineering Technology Research Center, and a post-doctoral research station. In May 2018, Hengrui Medicine was listed in Forbes’s top 100 world’s most innovative companies and ranked the 64th, where only 7 companies from China were on the list. Hengrui fully owns 8 manufacturing facilities for small and large molecules as well as medical devices. All facilities are approved and audited by NMPA, most also approved by US FDA, EDQM, TGA, and PMDA. Embracing the spirit of “Honesty and Trustworthiness, Quality First” as a business principle, Hengrui leads the Chinese markets for anti-cancer drugs, surgical anesthetics, specialized infusions, and contrast agents. To date, Hengrui has 10+ products approved in Europe, US, and Japan, covering injectables, oral formulations, and inhalational anesthetics, and has achieved remarkable sales in those markets. Pursuing the concept of “Excelling in Science, Enhancing Life”, Hengrui sees its future as a Chinese multi-national pharmaceutical corporation, and continuously strives for innovation, progress, and achievement of new breakthrough in the healthcare industry.
|Sales markets||Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America|
|Affiliated categories:||APIs |Finished Dosage Forms |Injectables More|
CPhI Worldwide 20195-7 November 2019 Frankfurt, Germany Visit us at stand 90B20 Book a meeting See our Exhibitor Profile See full Exhibitor List
CPhI North America 201930 April - 2 May 2019 Chicago, USA We were at stand 121 See our Exhibitor Profile See full Exhibitor List
CPhI South East Asia 201912-14 March 2019 Bangkok, Thailand We were at stand A16 See our Exhibitor Profile See full Exhibitor List
Our Top products
Sevoflurane Inhalation Anesthetic
Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl
isopropyl ether used as aninhalational anaesthetic for induction and
maintenance of general anesthesia.
Sevoflurane Inhalation Anesthetic was approved by CFDA and launched in ...
Desflurane, Liquid for Inhalation
Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anesthesia.
Chinese local GMP certificate will be got in 2018. US-ANDA Submitted; Netherlands, German and UK GMP Certificated.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation